1. [Untitled]
- Subjects
Combretastatin ,Pathology ,medicine.medical_specialty ,business.industry ,Combretastatin A1 Diphosphate ,Fat pad ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,medicine.anatomical_structure ,chemistry ,In vivo ,030220 oncology & carcinogenesis ,medicine ,Radiology, Nuclear Medicine and imaging ,Pyruvic acid ,Hyperpolarization (physics) ,business ,Perfusion ,Artery - Abstract
Purpose: A rat model was developed to enable direct administration of hyperpolarized 13C-labeled molecules into a tumorsupplying artery for magnetic resonance spectroscopy (MRS) studies of tumor metabolism. Methods: Rat P22 sarcomas were implanted into the right inguinal fat pad of BDIX rats such that the developing tumors received their principle blood supply directly from the right superior epigastric artery. Hyperpolarized 13C-molecules were either infused directly to the tumor through the epigastric artery or systemically through the contralateral femoral vein. Spectroscopic data were obtained on a 7 Tesla preclinical scanner. Results: Intra-arterial infusion of hyperpolarized 13C-pyruvate increased the pyruvate tumor signal by a factor of 4.6, compared with intravenous infusion, despite an approximately 7 times smaller total dose to the rat. Hyperpolarized glucose signal was detected at near-physiological systemic blood concentration. Pyruvate to lactate but not glucose to lactate metabolism was detected in the tumor. Hyperpolarized 13Clabeled combretastatin A1 diphosphate, a tumor vascular disrupting agent, showed an in vivo signal in the tumor. Conclusions: The model maximizes tumor substrate/drug delivery and minimizes T1 relaxation signal losses in addition to systemic toxicity. Therefore, it permits metabolic studies of hyperpolarized substrates with relatively short T1 and opens up the possibility for preclinical studies of hyperpolarized drug molecules.